title: Empiric treatment of protracted idiopathic purpura fulminans in an infant: a case report and review of the literature.
abstract: BACKGROUND
  Idiopathic purpura fulminans is a cutaneous thrombotic disorder usually caused by autoimmune-mediated protein C or S deficiency. This disorder typically presents with purpura and petechiae that eventually slowly or rapidly coalesce into extensive, necrotic eschars on the extremities. We present the first known case of idiopathic purpura fulminans consistent with prior clinical presentations in the setting of a prothrombotic genetic mutation, but without hallmark biochemical evidence of protein C or protein S deficiency. Another novel feature of our patient's presentation is that discontinuation of anti-coagulation has invariably led to recurrence and formation of new lesions, which is unexpected in idiopathic purpura fulminans because clearance of autoimmune factors should be followed by restoration of anti-coagulant function. Although this disease is rare, infants with suspected idiopathic purpura fulminans should be rapidly diagnosed and immediately anti-coagulated to prevent adverse catastrophic outcomes such as amputation and significant developmental delay.
  
  
  METHODS
  A six-month-old Caucasian boy was brought to our pediatric hospital service with a low-grade fever and subacute, symmetric, serpiginous, stellate, necrotic eschars on his forearms, legs and feet that eventually spread non-contiguously to his toes, thighs and buttocks. In contrast to his impressive clinical presentation, his serologic evaluation was normal, and he was not responsive to corticosteroids and antibiotics. Full-thickness skin biopsies revealed dermal vessel thrombosis, leading to a diagnosis of idiopathic purpura fulminans and successful treatment with low-molecular-weight heparin, which was transitioned to warfarin. Long-term management has included chronic anti-coagulation because of recurrence of lesions with discontinuation of treatment.
  
  
  CONCLUSIONS
  In infants with necrotic eschars, it is important to first consider infectious, inflammatory and hematologic etiologies. In the absence of etiology for protracted idiopathic purpura fulminans, management should include tissue biopsy, in which thrombotic findings warrant a trial of empiric anti-coagulation. Some infants, including our patient, may need long-term anti-coagulation, especially when the underlying etiology of coagulation remains unidentified and symptoms recur when treatment is halted. Given that our patient still requires anti-coagulation, he may have a yet to be identified autoimmune-mediated mechanism for his truly idiopathic case of protracted purpura fulminans.
authors: Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA. macheret.fima@mayo.edu.
authors: Fima
authors: F
authors: Macheret
authors: Kavitha N
authors: KN
authors: Pundi
authors: Eileen M
authors: EM
authors: Broomall
authors: Dawn M
authors: DM
authors: Davis
authors: Vilmarie
authors: V
authors: Rodriguez
authors: Chad K
authors: CK
authors: Brands
references: Br J Dermatol. 2009 Jul;161(1):181-3
references: 19545295
references: Blood. 1985 Jan;65(1):15-20
references: 3838081
references: Ann Hematol. 2003 Feb;82(2):118-120
references: 12601492
references: Semin Thromb Hemost. 1990 Oct;16(4):310-25
references: 2281320
references: J Pediatr. 1996 Mar;128(3):319-23
references: 8774497
references: J Thromb Haemost. 2005 Jun;3(6):1243-9
references: 15946215
references: J Pediatr. 1995 Sep;127(3):355-63
references: 7658262
references: Pediatr Dermatol. 1998 May-Jun;15(3):169-83
references: 9655311
references: Pediatr Hematol Oncol. 1999 Nov-Dec;16(6):561-4
references: 10599098
references: Am J Dis Child. 1991 Feb;145(2):218-20
references: 1994692
references: Clin Infect Dis. 1993 Aug;17(2):254-61
references: 8399877
references: N Engl J Med. 1987 Aug 27;317(9):571-2
references: 2956521
references: N Engl J Med. 1993 Jun 17;328(24):1753-7
references: 8497285
references: J Pediatr Hematol Oncol. 2004 Jan;26(1):25-7
references: 14707707
references: J Environ Pathol Toxicol Oncol. 2008;27(3):191-6
references: 18652566